person · Reporting owner

GOLDSMITH MARK A

Disclosed activity across 2 companies

Tapewire entity: 19850
SEC CIK: 0001246842

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Revolution Medicines, Inc.RVMD · Entity 606	Director · See Remarks	September 16, 2026	September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	267,117	Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-16 · Sale · Disposed 213 · Balance 267,117 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	253,342	Reported balance After 2026-09-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-16 · Sale · Disposed 13,775 · Balance 253,342 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 157,588 restricted stock units.
Common StockSEC Table I · non-derivative	IndirectTrust	594,060	Reported balance Holding disclosure · report date 2026-09-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 594,060 F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 61,424 F5: Held by Jonathan Goldsmith Revocable Trust.
Common StockSEC Table I · non-derivative	IndirectTrust	61,424	Reported balance Holding disclosure · report date 2026-09-16 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 61,424 F6: Held by Rebecca Goldsmith Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 157,588 restricted stock units.

F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

F5: Held by Jonathan Goldsmith Revocable Trust.

F6: Held by Rebecca Goldsmith Revocable Trust.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONSTELLATION PHARMACEUTICALS INC

Report date July 15, 2021 · Filed July 19, 2021

Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-07-15 transaction · row 1 1 source row Row 1 · 2021-07-15 · Disposition to issuer · Disposed 89,857 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57	Direct	Reported balance After 2021-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	Direct	Reported balance After 2021-07-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-15 · Disposition to issuer · Disposed 6,825 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12	Direct	Reported balance After 2021-07-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60	Direct	Reported balance After 2021-07-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-15 · Disposition to issuer · Disposed 12,446 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51	Direct	Reported balance After 2021-07-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-15 · Disposition to issuer · Disposed 9,083 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52	Direct	Reported balance After 2021-07-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2024 Filed Oct 3, 2024 20:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	7,978	$44.80	$357,408.82	Disclosure SEC source: 0001610717-24-000501 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,192 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $44.32 to $45.31, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
October 01, 2024 Filed Oct 3, 2024 20:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,000	$4.09	$40,900.00	Disclosure SEC source: 0001610717-24-000501 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
September 16, 2024 Filed Sep 18, 2024 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	11,715	$44.19	$517,630.79	Disclosure SEC source: 0001610717-24-000488 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,170 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 188,750 restricted stock units. Read SEC document
August 01, 2024 Filed Aug 2, 2024 21:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000411 · form4.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 281,229 Underlying: Common Stock · 10,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
August 01, 2024 Filed Aug 2, 2024 21:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,217	$46.48	$149,519.40	Disclosure SEC source: 0001610717-24-000411 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,885 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $46.23 to $46.77, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 210,375 restricted stock units. Read SEC document
August 01, 2024 Filed Aug 2, 2024 21:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	6,783	$45.60	$309,307.51	Disclosure SEC source: 0001610717-24-000411 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,102 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $45.23 to $46.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 210,375 restricted stock units. Read SEC document
August 01, 2024 Filed Aug 2, 2024 21:35 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,000	$4.09	$40,900.00	Disclosure SEC source: 0001610717-24-000411 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 210,375 restricted stock units. Read SEC document
July 12, 2024 Filed Jul 16, 2024 21:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000396 · form4.xml · derivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,229 Underlying: Common Stock · 25,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
July 12, 2024 Filed Jul 16, 2024 21:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$45.01	$225,059.00	Disclosure SEC source: 0001610717-24-000396 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 25,424 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F6 · price: This transaction was executed in multiple trades in prices ranging from $45.00 to $45.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F7 · ownership.nature: Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Read SEC document
July 12, 2024 Filed Jul 16, 2024 21:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$45.01	$225,058.00	Disclosure SEC source: 0001610717-24-000396 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 25,424 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $45.00 to $45.04, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust. Read SEC document
July 12, 2024 Filed Jul 16, 2024 21:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	25,000	$45.05	$1,126,205.00	Disclosure SEC source: 0001610717-24-000396 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,885 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $45.00 to $45.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 210,375 restricted stock units. Read SEC document
July 12, 2024 Filed Jul 16, 2024 21:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	25,000	$4.09	$102,250.00	Disclosure SEC source: 0001610717-24-000396 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 336,885 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Includes 210,375 restricted stock units. Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:14 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	11,950	$37.39	$446,769.87	Disclosure SEC source: 0001610717-24-000352 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,885 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.3863 to $37.3870, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. F4 · balance_after: Includes 210,375 RSUs. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000285 · form4.xml · derivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,229 Underlying: Common Stock · 7,500 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	901	$40.93	$36,880.90	Disclosure SEC source: 0001610717-24-000285 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 322,322 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F6 · price: This transaction was executed in multiple trades in prices ranging from $40.50 to $41.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Reflects the transfer of 138,057 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 232,000 restricted stock units. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,699	$39.99	$227,879.64	Disclosure SEC source: 0001610717-24-000285 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 323,223 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F5 · price: This transaction was executed in multiple trades in prices ranging from $39.41 to $40.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Reflects the transfer of 138,057 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 232,000 restricted stock units. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	900	$39.09	$35,181.81	Disclosure SEC source: 0001610717-24-000285 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,922 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $38.41 to $39.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Reflects the transfer of 138,057 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 232,000 restricted stock units. Read SEC document
June 03, 2024 Filed Jun 5, 2024 20:18 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	7,500	$4.09	$30,675.00	Disclosure SEC source: 0001610717-24-000285 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 329,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · balance_after: Reflects the transfer of 138,057 shares previously held directly by the Reporting Person into a family trust. F3 · balance_after: Includes 232,000 restricted stock units. Read SEC document
April 10, 2024 Filed Apr 13, 2024 00:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$35.34	$176,687.00	Disclosure SEC source: 0001610717-24-000206 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 30,424 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $35.00 to $35.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · ownership.nature: Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Read SEC document
April 10, 2024 Filed Apr 13, 2024 00:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$35.33	$176,658.50	Disclosure SEC source: 0001610717-24-000206 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Indirect · Trust Disclosed balance after: 30,424 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $35.00 to $35.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F5 · ownership.nature: Held by Jonathan Goldsmith Revocable Trust, previously Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Read SEC document
April 10, 2024 Filed Apr 13, 2024 00:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	7,500	$35.48	$266,121.75	Disclosure SEC source: 0001610717-24-000206 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,879 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 1, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $35.00 to $35.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 232,000 restricted stock units. Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:44 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,788	$31.58	$182,803.56	Disclosure SEC source: 0001610717-24-000171 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,379 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 232,000 RSUs. Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:55 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	314,000	$0.00 Strike: $29.80	$0.00	Disclosure SEC source: 0001610717-24-000133 · form4.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,000 Underlying: Common Stock · 314,000 shares Expires 2034-02-28 F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:55 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	90,000	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000133 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,167 F1 · balance_after: Includes 248,000 restricted stock units. Read SEC document
December 18, 2023 Filed Dec 20, 2023 22:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	8,165	$25.90	$211,488.20	Disclosure SEC source: 0001610717-23-000415 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376,167 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: This transaction was executed in multiple trades in prices ranging from $25.8996 to $25.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · balance_after: Includes 158,000 RSUs. Read SEC document
October 24, 2023 Filed Oct 24, 2023 23:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001610717-23-000314 · form4.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,446 Underlying: Common Stock · 35,000 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 24, 2023 Filed Oct 24, 2023 23:21 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	35,000	$0.49	$17,150.00	Disclosure SEC source: 0001610717-23-000314 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 174,000 restricted stock units. Read SEC document
September 18, 2023 Filed Sep 20, 2023 20:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	8,054	$31.31	$252,174.77	Disclosure SEC source: 0001610717-23-000294 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,332 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.0915 to $31.3108. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 174,000 RSUs. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	12,007	$0.00 Strike: $1.12	$0.00	Disclosure SEC source: 0001610717-23-000261 · form4.xml · derivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,479 Underlying: Common Stock · 12,007 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on November 22, 2022. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	17,993	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001610717-23-000261 · form4.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,503 Underlying: Common Stock · 17,993 shares Expires 2028-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on November 22, 2022. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$35.04	$175,219.00	Disclosure SEC source: 0001610717-23-000261 · form4.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 35,424 F8 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Rebecca Eve Goldsmith Trust on November 21, 2022. F9 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F10 · ownership.nature: Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$35.04	$175,191.00	Disclosure SEC source: 0001610717-23-000261 · form4.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · Trust Disclosed balance after: 35,424 F5 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Jonathan Henry Goldsmith Trust on November 21, 2022. F6 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F7 · ownership.nature: Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	30,000	$35.05	$1,051,563.00	Disclosure SEC source: 0001610717-23-000261 · form4.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,386 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on November 22, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 190,000 restricted stock units. F3 · balance_after: Includes 1,514 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	12,007	$1.12	$13,447.84	Disclosure SEC source: 0001610717-23-000261 · form4.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on November 22, 2022. F2 · balance_after: Includes 190,000 restricted stock units. F3 · balance_after: Includes 1,514 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. Read SEC document
September 01, 2023 Filed Sep 7, 2023 00:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	17,993	$0.54	$9,716.22	Disclosure SEC source: 0001610717-23-000261 · form4.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on November 22, 2022. F2 · balance_after: Includes 190,000 restricted stock units. F3 · balance_after: Includes 1,514 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	363,000	$0.00 Strike: $26.50	$0.00	Disclosure SEC source: 0001567619-23-004351 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,000 Underlying: Common Stock · 363,000 shares Expires 2033-02-28 F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:15 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	104,000	$0.00	$0.00	Disclosure SEC source: 0001567619-23-004351 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,872 F1 · balance_after: Includes 215,500 restricted stock units. Read SEC document
February 22, 2023 Filed Feb 24, 2023 00:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001567619-23-003701 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,446 Underlying: Common Stock · 45,000 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 22, 2023 Filed Feb 24, 2023 00:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	45,000	$0.49	$22,050.00	Disclosure SEC source: 0001567619-23-003701 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 111,500 restricted stock units. Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:56 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001567619-22-016223 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,446 Underlying: Common Stock · 10,000 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:56 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,000	$0.49	$4,900.00	Disclosure SEC source: 0001567619-22-016223 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 130,500 RSUs. Read SEC document
August 09, 2022 Filed Aug 10, 2022 21:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,336	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001567619-22-015481 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,446 Underlying: Common Stock · 10,336 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 09, 2022 Filed Aug 10, 2022 21:01 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,336	$0.49	$5,064.64	Disclosure SEC source: 0001567619-22-015481 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 130,500 RSUs. F5 · balance_after: Includes 937 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2022. Read SEC document
March 17, 2022 Filed Mar 22, 2022 00:02 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,023	$18.61	$19,042.22	Disclosure SEC source: 0001567619-22-007324 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,599 F4 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F5 · price: This transaction was executed in multiple trades in prices ranging from $18.1186 to $18.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · balance_after: Includes 140,000 RSUs. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:28 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	363,000	$0.00 Strike: $18.56	$0.00	Disclosure SEC source: 0001567619-22-006237 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,000 Underlying: Common Stock · 363,000 shares Expires 2032-02-29 F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2022 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:28 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	104,000	$0.00	$0.00	Disclosure SEC source: 0001567619-22-006237 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,622 F4 · balance_after: Includes 143,000 Restricted Stock Units. Read SEC document
December 17, 2021 Filed Dec 21, 2021 21:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,571	$24.41	$38,348.11	Disclosure SEC source: 0001567619-21-022400 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,622 F4 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F5 · balance_after: Includes 39,000 RSUs. Read SEC document
December 06, 2021 Filed Dec 8, 2021 21:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	37,721	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0001567619-21-021768 · doc1.xml · derivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,782 Underlying: Common Stock · 37,721 shares Expires 2027-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 06, 2021 Filed Dec 8, 2021 21:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	37,721	$0.49	$18,483.29	Disclosure SEC source: 0001567619-21-021768 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 42,000 RSUs. Read SEC document
September 17, 2021 Filed Sep 21, 2021 23:47 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,531	$30.02	$45,960.62	Disclosure SEC source: 0001567619-21-017414 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,472 F4 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F5 · balance_after: Includes 42,000 RSUs. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.